The difference in isoform specificity among JAK inhibitors might account for the tolerability and efficacy of each agent with an increased risk for anemia and other hematologic adverse events resulting from substantial JAK2 inhibition of tofacitinib compared to newer-generation agents [34,35]. This evidence concerns the gene JAK2 and anemia.